Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;1(4):163-75.
doi: 10.1177/2040622310380100.

Contemporary treatment of systemic lupus erythematosus: an update for clinicians

Maame B Amissah-Arthur  1 , Caroline Gordon
Affiliations

Contemporary treatment of systemic lupus erythematosus: an update for clinicians

Maame B Amissah-Arthur et al. Ther Adv Chronic Dis. 2010 Jul.

Abstract

The prognosis for patients with systemic lupus erythematosus (SLE) has improved significantly, with 20-year survival now approximately 80% owing partly to effective treatment. SLE treatment has evolved from the use of conventional drugs such as hydroxychloroquine and corticosteroids, nonspecific immunosuppressants including mycophenolate mofetil, to targeting selective components of the immune cascade with a view to increased efficacy, tolerability and safety profile. These novel treatments include B-cell-depleting antibodies and fusion proteins that block the costimulatory pathways of B and T cells. A discussion of these pharmacological options and ongoing research forms the basis of this review.

Keywords: B-cell therapy; SLE; autoimmune; immunosupressive; lupus; treatment.

PubMed Disclaimer

Conflict of interest statement

CG is or has been a paid consultant to, and received honoraria in the last 2 years from, Amgen, Aspreva/Vifor Pharma, Biogen, Bristol Myers Squibb, Genentech, GSK, Roche, Teva and UCB. CG has been in the speakers' bureau for BMS and UCB and has also received an unrestricted educational research grant from Aspreva/Vifor Pharma.

References

    1. Allison A.C. (2005) Mechanisms of action of mycophenolate mofetil. Lupus 14(Suppl. 1): S2–S8 - PubMed
    1. Allison M. (2010) PML problems loom for Rituxan. Nat Biotechnol 28: 105–106 - PubMed
    1. American College of Rheumatology (2009) Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): Results from the randomised, double-blind phase III LUNAR study. ACR/ARHP Annual Scientific Meeting, Philadelphia, PA, Presentation 1149
    1. Anderka M.T., Lin A.E., Abuelo D.N., Mitchell A.A., Rasmussen S.A. (2009) Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genetics A 149A: 1241–1248 - PubMed
    1. Appel G.B., Contreras G., Dooley M.A., Ginzler E.M., Isenberg D., Jayne D., et al. (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103–1112 - PMC - PubMed

LinkOut - more resources